Industry
Biotechnology
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 11:47 am
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 11:17 am
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 9:10 pm
Portfolio Pulse from Benzinga Newsdesk
February 27, 2024 | 9:09 pm
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 10:01 am
Portfolio Pulse from Benzinga Newsdesk
January 31, 2024 | 7:37 am
Portfolio Pulse from Benzinga Newsdesk
January 30, 2024 | 9:33 pm
Portfolio Pulse from Benzinga Newsdesk
January 29, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
January 02, 2024 | 3:58 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.